You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SCCHN

Showing 1 - 25 of 372
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head and Neck Squamous Cell Carcinoma Trial in Baltimore (Pembrolizumab, IO102-103)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Baltimore, Maryland
    Johns Hopkins University
Aug 2, 2023

Head Neck Cancer Trial in Billerica, Darmstadt (Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT))

Not yet recruiting
  • Head and Neck Cancer
  • Billerica, Massachusetts
  • +1 more
Sep 20, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Shanghai (MRG003, Cetuximab injection, Methotrexate Injection)

Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Feb 21, 2023

Squamous Cell Carcinoma of the Head and Neck Trial in Stanford ([18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.)

Completed
  • Squamous Cell Carcinoma of the Head and Neck
  • [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
  • Stanford, California
    Stanford Hospital and Clinics
Dec 1, 2022

Head Neck Cancer Trial in Baltimore, Chapel Hill, Philadelphia (Pembrolizumab, Intensity Modulated Radiation Therapy)

Active, not recruiting
Has Results
  • Head and Neck Cancer
  • Baltimore, Maryland
  • +2 more
Dec 7, 2022

Carcinoma, Squamous Cell of Head and Neck Trial in United States (Cetuximab, PD 0332991)

Active, not recruiting
Has Results
  • Carcinoma, Squamous Cell of Head and Neck
  • Cetuximab
  • PD 0332991
  • Atlanta, Georgia
  • +4 more
Nov 1, 2022

Squamous Cell Carcinoma of the Head and Neck Trial (Xevinapant, Placebo, cetuximab)

Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • (no location specified)
Jul 3, 2023

HNSCC Trial in Avignon, Rennes (Durvalumab)

Recruiting
  • HNSCC
  • Avignon, France
  • +1 more
Mar 10, 2022

Nivolumab in Squamous Cell Carcinoma of Head & Neck - Patient

Completed
  • Squamous Cell Carcinoma of the Head and Neck
  • Nivolumab
  • Mount Laurel, New Jersey
    Local Institution
May 2, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Essen (Atezolizumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Essen, Germany
    University Hospital Essen
Nov 2, 2022

SCCHN, Squamous Cell Carcinoma Trial in Birmingham (Cisplatin)

Recruiting
  • SCCHN
  • Squamous Cell Carcinoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jan 5, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Neck Cancer Metastatic Trial in Baltimore (Nivolumab 480mg and

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Nivolumab 480mg and surgical resection
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Feb 25, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Shanghai (Docetaxel, Nivolumab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Shanghai, Shanghai, China
    Guo Ye
Jan 27, 2022

Carcinoma, Squamous Cell, Head Neck Cancer Trial in Lexington (Cisplatin, XRT)

Recruiting
  • Carcinoma, Squamous Cell
  • Head and Neck Cancer
  • Lexington, Kentucky
    University of Kentucky
Nov 17, 2021

Squamous Cell Carcinoma of Head and Neck Trial in Italy (Nivolumab 240 MG in 24 ML Injection)

Completed
  • Squamous Cell Carcinoma of Head and Neck
  • Nivolumab 240 MG in 24 ML Injection
  • Bergamo, Italy
  • +22 more
Apr 4, 2023

Colorectal Cancer Metastatic, Squamous Cell Carcinoma of Head and Neck Trial (WU-NK-101 - Dose Escalation, Cetuximab - Dose

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Squamous Cell Carcinoma of Head and Neck
  • WU-NK-101 - Dose Escalation
  • +3 more
  • (no location specified)
Dec 30, 2022

Head Neck Cancer, Larynx Trial in Lexington (Low dose fractionated radiation - 80cGy with chemo, Docetaxel and Carboplatin AUC

Active, not recruiting
Has Results
  • Head and Neck Cancer
  • Larynx
  • Low dose fractionated radiation - 80cGy with chemotherapy
  • Docetaxel and Carboplatin AUC 6
  • Lexington, Kentucky
    University of Kentucky, Markey Cancer Center
Aug 29, 2022

Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +2 more
  • RP3
  • +3 more
  • (no location specified)
Feb 21, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

First Line Recurrent/Metastatic Squamous Cell Carcinoma of Head

Completed
  • Squamous Cell Carcinoma of the Head and Neck
    • Parsippany, New Jersey
      Medical Data Analytics
    Nov 15, 2021

    HNSCC Trial in Lorient (Cetuximab, avelumab, Cisplatin)

    Active, not recruiting
    • HNSCC
    • Lorient, France
      Centre Hospitalier Bretagne Sud
    Mar 10, 2022

    Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder Trial in Spain, United Kingdom,

    Recruiting
    • Lung Cancer Non Small Cell
    • +2 more
    • IO102-IO103 in combination with pembrolizumab
    • Duarte, California
    • +18 more
    Dec 15, 2022

    Larynx, Lip, Oral Cancer Trial in Chapel Hill, Charleston (Durvalumab, Intensity Modulated Radiotherapy Treatments)

    Active, not recruiting
    • Larynx
    • +3 more
    • Durvalumab
    • Intensity Modulated Radiotherapy Treatments
    • Chapel Hill, North Carolina
    • +1 more
    May 26, 2022

    Nivolumab in Germany With Squamous Cell Carcinoma of Head and

    Active, not recruiting
    • Head and Neck Cancer
      • Leipzig, Germany
        Local Institution
      Aug 11, 2021

      Squamous Cell Carcinoma of the Head and Neck Trial in United States (SNS-301, Pembrolizumab)

      Terminated
      Has Results
      • Squamous Cell Carcinoma of the Head and Neck
      • San Francisco, California
      • +9 more
      Dec 6, 2022